| Michael H Broderdorf, MD | |
|
401 16th Ave Nw Ste 106, Rochester, MN 55901-1853 | |
| (507) 258-4680 | |
| Not Available |
| Full Name | Michael H Broderdorf |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 401 16th Ave Nw Ste 106, Rochester, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346209301 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 38976 (Minnesota) | Secondary |
| 207P00000X | Emergency Medicine | 38976 (Minnesota) | Primary |
| Entity Name | Minnesota Mobile Exams Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255906426 PECOS PAC ID: 1557767423 Enrollment ID: O20210901003028 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have shown that monitoring treatment adherence to AIDS therapy is a simple blood-free way to monitor risk of disease progression. The international study was published in the May issue of the journal PLoS Medicine.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).
As people go about their daily activities, complex fluctuations in their movement occur without conscious thought. These fluctuations - known as fractal motor activity regulation (FMAR) - and their changes are not readily detectable to the naked eye, but FMAR patterns can be recorded using a wristwatch-like device known as an actigraph.
Writing in the "UHC Forward" blog, Nkem Wellington, program officer at the Results for Development Institute (R4D), summarizes a debate that took place on the Performance-Based Financing Community of Practice online discussion forum following the December 12 U.N. General Assembly vote on the "Global health and foreign policy" draft resolution, which focused on universal health coverage (UHC).
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael H Broderdorf, MD 401 16th Ave Nw Ste 106, Rochester, MN 55901-1853 Ph: (507) 258-4680 | Michael H Broderdorf, MD 401 16th Ave Nw Ste 106, Rochester, MN 55901-1853 Ph: (507) 258-4680 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have shown that monitoring treatment adherence to AIDS therapy is a simple blood-free way to monitor risk of disease progression. The international study was published in the May issue of the journal PLoS Medicine.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).
As people go about their daily activities, complex fluctuations in their movement occur without conscious thought. These fluctuations - known as fractal motor activity regulation (FMAR) - and their changes are not readily detectable to the naked eye, but FMAR patterns can be recorded using a wristwatch-like device known as an actigraph.
Writing in the "UHC Forward" blog, Nkem Wellington, program officer at the Results for Development Institute (R4D), summarizes a debate that took place on the Performance-Based Financing Community of Practice online discussion forum following the December 12 U.N. General Assembly vote on the "Global health and foreign policy" draft resolution, which focused on universal health coverage (UHC).
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
› Verified 9 days ago
Dr. Sara Ann Schroeder Hevesi, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
David W Claypool, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Fernanda Bellolio, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Kristofer William Roberts, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jonathan F. Thomas, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Jessica Stanich, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Bergthor Steinn Jonsson, CAND.MED. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |